Range
33.5 - 35.51
Vol / Avg.
905.2K/766.7K
Div / Yield
-
52 Wk
33.5 - 56.4
Mkt Cap
4.8B
Payout Ratio
-
Open
35.05
P/E
12.13
EPS
1.53
Shares
140.8M
Outstanding
140.8M
Total Float
120.9M
load more
Sector: Health Care.Industry: Biotechnology
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Earnings

see more
Q4 2021Est.ActualSurprise
EPS
(EXPECTED)2022-02-22
REV
Q3 2021Est.ActualSurprise
EPS0.4200.550 0.1300
REV101.940M115.830M13.890M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Halozyme Therapeutics Questions & Anwsers

Q

How do I buy Halozyme Therapeutics (HALO) stock?

A

You can purchase shares of Halozyme Therapeutics (NASDAQ: HALO) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Halozyme Therapeutics's (HALO) competitors?

Q

What is the target price for Halozyme Therapeutics (HALO) stock?

A

The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by Wells Fargo on November 24, 2021. The analyst firm set a price target for 58.00 expecting HALO to rise to within 12 months (a possible 71.34% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Halozyme Therapeutics (HALO)?

A

The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $33.85 last updated Fri Nov 26 2021 18:00:03 GMT+0000 (Coordinated Universal Time).

Q

Does Halozyme Therapeutics (HALO) pay a dividend?

A

There are no upcoming dividends for Halozyme Therapeutics.

Q

When is Halozyme Therapeutics (NASDAQ:HALO) reporting earnings?

A

Halozyme Therapeutics’s $Q4 earnings are confirmed for after-market on February 22, 2022.

Q

Is Halozyme Therapeutics (HALO) going to split?

A

There is no upcoming split for Halozyme Therapeutics.

Q

What sector and industry does Halozyme Therapeutics (HALO) operate in?

A

Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.